Phase I/II Study of AZD2014 given in combination with palbociclib on a background of fulvestrant for treatment of advanced ER + breast cancer that is locally advanced or has spread to other parts of the body

Femme Homme

| Pays :
| Organes :
| Spécialités :

Extrait

PARTS A, B1, B2: To investigate the safety and tolerability of the triplet combination (AZD2014 and palbociclib on a background of fulvestrant) in the patient groups. PART B3: To investigate the impact on exposure to AZD2014 and palbociclib when administered in the triplet combination compared to each drug without the other in the Part B3 patient group. PART C: To assess the efficacy of the triplet combination compared to the doublet combination through assessment of Progression Free Survival in the Part C patient group.

Critère d'inclusion

Locally advanced or metastatic estrogen receptor positive breast cancer

Kusajili – Centralise les essais cliniques mondiaux

Phase I/II Study of AZD2014 given in combination with palbociclib on a background of fulvestrant for treatment of advanced ER + breast cancer that is locally advanced or has spread to other parts of t...